ScoreWhy is Zevra Therapeutics, Inc. ?
1
With a growth in Net Sales of 26.86%, the company declared Outstanding results in Jun 25
- ROCE(HY) Highest at 3.53%
- RAW MATERIAL COST(Y) Fallen by -187.81% (YoY)
- CASH AND EQV(HY) Highest at USD 265.24 MM
2
With ROE of -232.30%, it has a risky valuation with a 12.34 Price to Book Value
- Over the past year, while the stock has generated a return of -11.49%, its profits have fallen by -73.8%
3
High Institutional Holdings at 76.89%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 4.01% over the previous quarter.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Zevra Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zevra Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Zevra Therapeutics, Inc.
-7.87%
1.37
59.31%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
23.21%
EBIT Growth (5y)
-288.18%
EBIT to Interest (avg)
-14.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.25
Tax Ratio
22.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
76.89%
ROCE (avg)
10.83%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.34
EV to EBIT
-7.02
EV to EBITDA
-7.71
EV to Capital Employed
12.91
EV to Sales
12.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-183.97%
ROE (Latest)
-232.30%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend43What is working for the Company
ROCE(HY)
Highest at 3.53%
RAW MATERIAL COST(Y)
Fallen by -187.81% (YoY
CASH AND EQV(HY)
Highest at USD 265.24 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -119.71 %
INVENTORY TURNOVER RATIO(HY)
Highest at 48.83 times
DEBTORS TURNOVER RATIO(HY)
Highest at 4.56 times
NET SALES(Q)
Highest at USD 25.88 MM
PRE-TAX PROFIT(Q)
Highest at USD 136.37 MM
NET PROFIT(Q)
Highest at USD 132.47 MM
EPS(Q)
Highest at USD 1.36
-5What is not working for the Company
INTEREST(HY)
At USD 3.98 MM has Grown at 39.82%
Here's what is working for Zevra Therapeutics, Inc.
Net Sales
At USD 25.88 MM has Grown at 155.06%
over average net sales of the previous four periods of USD 10.15 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 136.37 MM has Grown at 793.31%
over average net sales of the previous four periods of USD -19.67 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 132.47 MM has Grown at 656.01%
over average net sales of the previous four periods of USD -23.82 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 25.88 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
Highest at USD 136.37 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 132.47 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 1.36
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 265.24 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -119.71 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 48.83 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 4.56 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -187.81% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 1.65 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Zevra Therapeutics, Inc.
Interest
At USD 3.98 MM has Grown at 39.82%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
